Abiopharma

🔍 Warren Eric (Executive)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Acquired 104,124 shares of Common Stock at $13.24 per share (Direct)
  Date: 2026-06-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 142,524.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 104,124 shares of Common Stock at $25.8953 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,400.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 104,124 shares of Stock Option at $13.24 per share (Derivative)
  Date: 2026-06-26 | Code: M | Expires: 2035-04-21 | equity_swap_involved: 0 | shares_owned_after: 252,876.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
• F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.8941 to $25.9100. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
• F3: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.